Monte Rosa Therapeutics Inc (GLUE)

Mar 29, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Holdings Boosted by Charles Schwab Investment Management Inc. - Defense World

Mar 29, 2025

Mar 27, 2025

Chandra Leo Spends US$58k On Monte Rosa Therapeutics Stock - simplywall.st

Mar 27, 2025

Mar 26, 2025

Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock - Investing.com Australia

Mar 26, 2025

Mar 25, 2025

Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Position Lifted by Bank of New York Mellon Corp - Defense World

Mar 25, 2025

Mar 24, 2025

Monte Rosa Therapeutics: Exercise Extreme Caution (NASDAQ:GLUE) - Seeking Alpha

Mar 24, 2025

Mar 24, 2025

FY2029 Earnings Estimate for GLUE Issued By Wedbush - Defense World

Mar 24, 2025

Mar 23, 2025

Wells Fargo & Company Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - Defense World

Mar 23, 2025

Mar 22, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 22, 2025

Mar 22, 2025

Wedbush Reaffirms Outperform Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World

Mar 22, 2025

Mar 22, 2025

Promising Clinical Developments and Strategic Partnerships Drive Buy Rating for Monte Rosa Therapeutics - TipRanks

Mar 22, 2025

Mar 22, 2025

Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 - MSN

Mar 22, 2025

Mar 21, 2025

Monte Rosa Therapeutics Earnings Call Highlights Progress and Strategic Shifts - TipRanks

Mar 21, 2025

Mar 21, 2025

Positive signs for Monte Rosa in early data - The Pharma Letter

Mar 21, 2025

Mar 20, 2025

Monte Rosa Therapeutics Reports Strong Q4 2024 Results - TipRanks

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics announces results from MRT-6160, MRT-2359 programs - TipRanks

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics shares surge on strong Q4 revenue beat - Investing.com

Mar 20, 2025

Mar 20, 2025

Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders - Benzinga

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics earnings missed by $0.54, revenue topped estimates - Investing.com Canada

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics shares surge on strong Q4 revenue beat By Investing.com - Investing.com Australia

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics Files $400 Million Mixed Shelf -March 20, 2025 at 10:11 am EDT - MarketScreener

Mar 20, 2025

Mar 20, 2025

Earnings call transcript: Monte Rosa Therapeutics Q4 2024 shows strong cash runway - Investing.com

Mar 20, 2025

Mar 20, 2025

MONTE ROSA THERAPEUTICS Earnings Results: $GLUE Reports Quarterly Earnings - Nasdaq

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics sees cash runway into 2028 - TipRanks

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics reports Q4 revenue $60.6M, consensus $51.9M - TipRanks

Mar 20, 2025

Mar 20, 2025

Updated: Monte Rosa reports first data for molecular glue program licensed to Novartis - Endpoints News

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics Reports Q4 2024 Financial Results - TipRanks

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics Announces Fourth Quarter 2024 - GlobeNewswire

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs - The Manila Times

Mar 20, 2025

Mar 20, 2025

Monte Rosa's Breakthrough: 90% Target Degradation Success Powers $60M Quarter - StockTitan

Mar 20, 2025

Mar 19, 2025

Molecular Glues Market to Register Stunning Growth During the Forecast Period (2025-2034) | DelveInsight - Lelezard

Mar 19, 2025

Mar 16, 2025

When (GLUE) Moves Investors should Listen - news.stocktradersdaily.com

Mar 16, 2025

Mar 16, 2025

Lexeo Therapeutics (NASDAQ:LXEO) & Monte Rosa Therapeutics (NASDAQ:GLUE) Critical Survey - Defense World

Mar 16, 2025

Mar 15, 2025

What is Lifesci Capital’s Forecast for GLUE FY2024 Earnings? - Defense World

Mar 15, 2025

Mar 14, 2025

Monte Rosa Therapeutics (NASDAQ:GLUE) Coverage Initiated at Lifesci Capital - Defense World

Mar 14, 2025

Mar 12, 2025

LifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform Recommendation - Nasdaq

Mar 12, 2025

Mar 11, 2025

Monte Rosa Therapeutics to Present Pipeline Update and - GlobeNewswire

Mar 11, 2025

Mar 11, 2025

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - The Manila Times

Mar 11, 2025

Mar 11, 2025

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year ... - The Bakersfield Californian

Mar 11, 2025

Mar 11, 2025

Monte Rosa Reveals Critical Clinical Data from Two Cancer Drug Trials Plus 2024 Earnings - StockTitan

Mar 11, 2025

Mar 09, 2025

Rhumbline Advisers Acquires 9,323 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Mar 09, 2025

Mar 07, 2025

3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance

Mar 07, 2025

Mar 06, 2025

Monte Rosa Therapeutics (GLUE) Projected to Post Earnings on Thursday - Defense World

Mar 06, 2025